Company intelligence / Profile preview

Blendair

Watertown, Massachusetts, United Statesdnb.com ↗

Ownership: Private
Development stage: Other

Overview

Developed innovative platforms for integrative combination medicines and miniaturized biologic drug conjugates aimed at overcoming biological barriers in solid tumor treatment. Lead program was a personalized cisplatin prodrug with anticipated clinical entry around mid‑2015.

Therapeutic areas: Oncology
Modalities: Small moleculeBiologic drug conjugateNanoparticle-based therapy
Industry: Biotech

Partnerships

Collaborations with pharmaceutical partners anticipated but none specifically disclosed by name.

Beyond the preview

Go deeper on Blendair.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blendair.

Explore the full profile